Ray Dalio's ABT Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 122,694 shares of Abbott Laboratories (ABT) worth $15.37 M, representing 0.06% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Ray Dalio has maintained a long-term strategic position in ABT, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2022, adding 861,685 shares. Largest reduction occurred in Q3 2024, reducing 960,854 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Abbott Laboratories (ABT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Abbott Laboratories (ABT) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +3,459 | Add 2.90% | 122,694 | $125.29 |
| Q3 2025 | +62,345 | Add 109.59% | 119,235 | $133.94 |
| Q2 2025 | -15,940 | Reduce 21.89% | 56,890 | $136.01 |
| Q1 2025 | -118,896 | Reduce 62.01% | 72,830 | $132.65 |
| Q4 2024 | -515,889 | Reduce 72.91% | 191,726 | $113.11 |
| Q3 2024 | -960,854 | Reduce 57.59% | 707,615 | $114.01 |
| Q2 2024 | -67,688 | Reduce 3.90% | 1.67 M | $103.91 |
| Q1 2024 | -161,062 | Reduce 8.49% | 1.74 M | $113.66 |
| Q4 2023 | -177,244 | Reduce 8.54% | 1.9 M | $110.07 |
| Q3 2023 | +251,477 | Add 13.79% | 2.07 M | $96.85 |
| Q2 2023 | -335,716 | Reduce 15.55% | 1.82 M | $109.02 |
| Q1 2023 | -62,089 | Reduce 2.80% | 2.16 M | $101.26 |
| Q4 2022 | -859,163 | Reduce 27.90% | 2.22 M | $109.79 |
| Q3 2022 | +280,041 | Add 10.00% | 3.08 M | $96.76 |
| Q2 2022 | -245,517 | Reduce 8.06% | 2.8 M | $108.65 |
| Q1 2022 | +861,685 | Add 39.46% | 3.05 M | $118.36 |
| Q4 2021 | +313,352 | Add 16.75% | 2.18 M | $140.74 |
| Q3 2021 | +73,563 | Add 4.09% | 1.87 M | $118.13 |
| Q2 2021 | +708,381 | Add 65.08% | 1.8 M | $115.93 |
| Q1 2021 | +175,523 | Add 19.23% | 1.09 M | $119.84 |
| Q4 2020 | +479,463 | Add 110.61% | 912,926 | $109.49 |
| Q3 2020 | +433,463 | New Buy | 433,463 | $108.83 |
| Q2 2020 | -54,586 | Sold Out | 0 | $0.00 |
| Q1 2020 | +54,586 | New Buy | 54,586 | $78.90 |
| Q4 2017 | -7,623 | Sold Out | 0 | $0.00 |
| Q3 2017 | +7,623 | New Buy | 7,623 | $53.39 |
| Q1 2017 | -80,200 | Sold Out | 0 | $0.00 |
| Q4 2016 | +18,200 | Add 29.35% | 80,200 | $38.40 |
| Q3 2016 | -42,100 | Reduce 40.44% | 62,000 | $42.29 |
| Q2 2016 | +92,700 | Add 813.16% | 104,100 | $39.31 |
| Q1 2016 | -27,457 | Reduce 70.66% | 11,400 | $41.84 |
| Q4 2015 | -43,600 | Reduce 52.88% | 38,857 | $44.91 |
| Q3 2015 | +54,000 | Add 189.76% | 82,457 | $40.21 |
| Q2 2015 | +28,457 | New Buy | 28,457 | $49.09 |
| Q1 2015 | -45,000 | Sold Out | 0 | $0.00 |
| Q4 2014 | +45,000 | New Buy | 45,000 | $45.02 |
| Q3 2014 | -17,700 | Sold Out | 0 | $0.00 |
| Q2 2014 | +500 | Add 2.91% | 17,700 | $40.90 |
| Q1 2014 | +17,200 | New Buy | 17,200 | $38.49 |
| Q4 2013 | -118,700 | Sold Out | 0 | $0.00 |
| Q3 2013 | +118,700 | New Buy | 118,700 | $33.19 |
Ray Dalio's Abbott Laboratories Investment FAQs
Ray Dalio first purchased Abbott Laboratories (ABT) in Q3 2013, acquiring 118,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Abbott Laboratories (ABT) for 41 quarters since Q3 2013.
Ray Dalio's largest addition to Abbott Laboratories (ABT) was in Q1 2022, adding 3,045,430 shares worth $360.46 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 122,694 shares of Abbott Laboratories (ABT), valued at approximately $15.37 M.
As of the Q4 2025 filing, Abbott Laboratories (ABT) represents approximately 0.06% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Abbott Laboratories (ABT) was 3,079,954 shares, as reported at the end of Q3 2022.